首页|GLP-1-RA类药物市场现状分析

GLP-1-RA类药物市场现状分析

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
胰高血糖素样肽-1受体激动剂(GLP-1-RA)类药物凭借降糖平稳,适应证广泛,用药依从性强的优点,在最近十几年里,发展迅速,一跃成为糖尿病药物中销售额最大的品类,但因价格高,上市时间短,普及率不足10％,故市场前景有待挖掘.GLP-1-RA类药物市场竞争激烈,有多款重磅炸弹药物问世,甚至有年销售额超百亿美元的产品.本文从作用机理、分类、市场演变史、专利状态,国内仿制药现状及国内医疗政策方面描述了GLP-1-RA类药物特点和市场现状.
Analysis of the Current Situation of the GLP-1-RA Market
GLP-1-RA(Glucagon-like Peptide-1 Receptor Agonists)medications have gained rapid traction because of their superior blood sugar regulation capabilities,extensive therapeutic indications,and high levels of patient adherence.In the past ten years,it has become the category with the largest sales among diabetes drugs.However,the penetration rate is less than 10％because of the expensive price and quick time to market,indicating a huge market opportunity.The market for GLP-1-RA is highly competitive,with several blockbuster drugs coming out,and even products with annual sales exceeding US$10 billion.This article describes the characteristics and market status of GLP-1-RA from the aspects of mechanism of action,classification,market evolution history,patent status,domestic generic drug status and domestic medical policy.

GLP-1-RA(Glucagon-like peptide-1 receptor agonists)diabetesmechanism of actionmarketpatentgeneric drugmedical policy

李进军、赵晨、王辂、李端华

展开 >

成都大学抗生素研究与再评价四川省重点实验室,成都 610052

胰高血糖素样肽-1受体激动剂(GLP-1-RA) 糖尿病 作用机理 市场 专利 仿制药 医疗政策

四川省科技厅国际科技合作项目四川省科技厅国际科技合作项目成都市科技局国际合作项目

2020YFH00132021YFH00162020-GH02-00031-HZ

2024

国外医药(抗生素分册)
中国医药集团总公司四川抗菌素工业研究所,中国医学科学院医药生物技术研究所

国外医药(抗生素分册)

影响因子：0.852
ISSN：1001-8751
年,卷(期)：2024.45(3)
  • 26